# Filing Detail

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001628280-23-013560
Filing Date
2023-04-27
Accepted
2023-04-27 16:01:40
Documents
4

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFA14A | a2023defa14a.htm | DEFA14A | 24904
2 |  | image_0.jpg | GRAPHIC | 41860
3 |  | img01_pagex1.jpg | GRAPHIC | 1410821
4 |  | img01_pagex2.jpg | GRAPHIC | 673910
| Complete submission text file | 0001628280-23-013560.txt |  | 2952810

Mailing Address 11055 FLINTKOTE AVENUE SAN DIEGO CA 92121
Business Address 11055 FLINTKOTE AVENUE SAN DIEGO CA 92121 858-952-7570
Cardiff Oncology, Inc. (Filer) CIK: 0001213037 (see all company filings)

EIN.: 272004382 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-35558 | Film No.: 23856618
SIC: 2836 Biological Products, (No Diagnostic Substances)